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Early noninvasive ventilation prevents extubation failure in at-risk patients
Synopsis protocols of each unit. Outcomes: Respiratory failure in the first three days, mortality in the intensive care unit, and 90-day survival. Respiratory failure was defined as at least two of the following: respiratory acidosis; hypoxaemia at an inspired oxygen fraction of 0.5 or more; respiratory rate > 35/minute; decreased consciousness, agitation or diaphoresis; and respiratory muscle fatigue or increased work of breathing. A subgroup analysis was performed based on the presence of hypercapnia during the spontaneous breathing trial. Results: Compared with the control group, respiratory failure was less frequent (Relative Risk 0.5, 95% confidence interval (CI) 0.3 to 0.9). This indicates that the number of patients that needed to be treated (NNT) with early NPPV to prevent one case of respiratory failure was 6 (95% CI 3 to 36). Mortality in the intensive care unit was significantly lower in the NPPV group, with the NNT to prevent one death being 8 (95% CI 5 to 30). In the subgroup analysis of those with hypercapnia during the spontaneous breathing trial, this benefit was greater (NNT 6, 95% CI 3 to 61). Survival to 90 days showed no significant difference between the NPPV and control groups overall. Among the subgroup with hypercapnia during the spontaneous breathing trial, however, the difference in survival was significant (NPPV 85% vs control 50%, p = 0.006). Conclusion: NPPV for 24 hours post-extubation in patients at high risk of respiratory failure reduced the risk of early respiratory failure and mortality. [Relative Risk and NNT calculated by CAP Editor from data in paper.]
Commentary
Non-invasive ventilation (NIV) has become standard treatment for patients with acute hypercapnic exacerbations of COPD. Improved survival is attributed predominantly to the avoidance of prolonged endotracheal intubation, reducing the risk of infective complications and organ dysfunction. Furthermore, recent literature demonstrates improved survival when NIV is used to facilitate early extubation in patients weaning from mechanical ventilation, although a significant proportion of patients included in these trials had chronic respiratory disease.
More recently, studies have evaluated NIV as a potential therapy to prevent re-intubation and its associated complications following extubation failure. The largest trial (Esteban et al 2004) used NIV as a recovery strategy in patients who developed respiratory failure within 48 hours after extubation. Results showed increased mortality in NIV treated patients compared to those treated with standard medical care. This was linked to a longer time between the development of respiratory failure and re-intubation in the NIV group. However, a secondary analysis revealed a trend towards improved survival in NIV-treated patients with COPD.
The current study applied NIV immediately after extubation in patients with an increased risk of developing respiratory failure. NIV was associated with reduced risk of respiratory failure and improved ICU mortality but did not affect 90-day survival. However, NIV reduced ICU and 90-day mortality in those patients who developed hypercapnia during their spontaneous breathing trial. Unsurprisingly, 98% of this group had chronic respiratory disease. Rightly the authors recommend further confirmatory studies, but given its proven benefit in avoiding and facilitating early liberation from invasive mechanical ventilation, it should probably not surprise us that early NIV is beneficial in this patient group.
There is however some room for caution. In such studies, NIV is applied in a 'standardised' fashion, in centres with significant NIV experience or following extensive educational programs. This 'structure' is a crucial component of the therapy, and needs to be put in place if potential benefits are to be realised by individual centres.
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